Scopus Biopharma OTC Stock Forward View - Triple Exponential Smoothing
| SCPS Stock | USD 0.0006 0.0002 50.00% |
Scopus OTC Stock outlook is based on your current time horizon.
The value of RSI of Scopus Biopharma's otc stock price is slightly above 69. This usually implies that the otc stock is rather overbought by investors at this time. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Scopus, making its price go up or down. Momentum 69
Buy Stretched
Oversold | Overbought |
It is a matter of debate whether otc price prediction based on information in financial news can generate signals. We use our internally-built news screening methodology to estimate the value of Scopus Biopharma based on different types of headlines from major news networks to social media. Using Scopus Biopharma hype-based prediction, you can estimate the value of Scopus Biopharma from the perspective of Scopus Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
The Triple Exponential Smoothing forecasted value of Scopus Biopharma on the next trading day is expected to be 0.0006 with a mean absolute deviation of 0.000028 and the sum of the absolute errors of 0. Scopus Biopharma after-hype prediction price | USD 3.66E-4 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as otc price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Scopus |
Scopus Biopharma Additional Predictive Modules
Most predictive techniques to examine Scopus price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Scopus using various technical indicators. When you analyze Scopus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Scopus Biopharma Triple Exponential Smoothing Price Forecast For the 3rd of February
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Scopus Biopharma on the next trading day is expected to be 0.0006 with a mean absolute deviation of 0.000028, mean absolute percentage error of 0, and the sum of the absolute errors of 0.Please note that although there have been many attempts to predict Scopus OTC Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Scopus Biopharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Scopus Biopharma OTC Stock Forecast Pattern
| Backtest Scopus Biopharma | Scopus Biopharma Price Prediction | Research Analysis |
Scopus Biopharma Forecasted Value
In the context of forecasting Scopus Biopharma's OTC Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Scopus Biopharma's downside and upside margins for the forecasting period are 0.000006 and 13.97, respectively. We have considered Scopus Biopharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Scopus Biopharma otc stock data series using in forecasting. Note that when a statistical model is used to represent Scopus Biopharma otc stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0 |
| MAPE | Mean absolute percentage error | 0.0564 |
| SAE | Sum of the absolute errors | 0.0016 |
Predictive Modules for Scopus Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Scopus Biopharma. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Scopus Biopharma After-Hype Price Density Analysis
As far as predicting the price of Scopus Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Scopus Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of OTC Stock prices, such as prices of Scopus Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Scopus Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Scopus Biopharma's otc stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Scopus Biopharma's historical news coverage. Scopus Biopharma's after-hype downside and upside margins for the prediction period are 0.00 and 13.97, respectively. We have considered Scopus Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Scopus Biopharma is out of control at this time. Analysis and calculation of next after-hype price of Scopus Biopharma is based on 3 months time horizon.
Scopus Biopharma OTC Stock Price Outlook Analysis
Have you ever been surprised when a price of a OTC Stock such as Scopus Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Scopus Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the OTC price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Scopus Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.56 | 13.97 | 0.00 | 0.00 | 0 Events / Month | 1 Events / Month | Within a week |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.0006 | 0.0004 | 39.06 |
|
Scopus Biopharma Hype Timeline
Scopus Biopharma is at this time traded for 0.0006. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Scopus is projected to decline in value after the next headline, with the price expected to drop to 3.66E-4. The average volatility of media hype impact on the company price is insignificant. The price decrease on the next news is expected to be -39.06%, whereas the daily expected return is at this time at 1.56%. The volatility of related hype on Scopus Biopharma is about 0.0%, with the expected price after the next announcement by competition of 0.00. About 51.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.51. Scopus Biopharma had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be within a week. Check out Historical Fundamental Analysis of Scopus Biopharma to cross-verify your projections.Scopus Biopharma Related Hype Analysis
Having access to credible news sources related to Scopus Biopharma's direct competition is more important than ever and may enhance your ability to predict Scopus Biopharma's future price movements. Getting to know how Scopus Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Scopus Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| RCAR | RenovaCare | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| RGIN | Regenicin | 0.00 | 0 per month | 0.00 | 0.09 | 0.00 | 0.00 | 190.00 | |
| VOQP | VioQuest Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| MDIT | Medite Cancer Diagnostics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| QBIO | Q BioMed | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PARD | Poniard Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| OZYMF | Orphazyme AS | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| VAXX | Vaxxinity | 0.00 | 0 per month | 121.46 | 0.28 | 6,775 | (99.00) | 15,000 | |
| LOWLF | Lowell Farms | 0.00 | 0 per month | 19.82 | 0.16 | 70.48 | (36.31) | 1,900 | |
| PXMD | PaxMedica Common Stock | 0.00 | 7 per month | 0.00 | 0.13 | 0.00 | 0.00 | 4,998 |
Other Forecasting Options for Scopus Biopharma
For every potential investor in Scopus, whether a beginner or expert, Scopus Biopharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Scopus OTC Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Scopus. Basic forecasting techniques help filter out the noise by identifying Scopus Biopharma's price trends.Scopus Biopharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Scopus Biopharma otc stock to make a market-neutral strategy. Peer analysis of Scopus Biopharma could also be used in its relative valuation, which is a method of valuing Scopus Biopharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Scopus Biopharma Market Strength Events
Market strength indicators help investors to evaluate how Scopus Biopharma otc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Scopus Biopharma shares will generate the highest return on investment. By undertsting and applying Scopus Biopharma otc stock market strength indicators, traders can identify Scopus Biopharma entry and exit signals to maximize returns.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.5 | |||
| Day Median Price | 6.0E-4 | |||
| Day Typical Price | 6.0E-4 | |||
| Price Action Indicator | 1.0E-4 | |||
| Period Momentum Indicator | 2.0E-4 | |||
| Relative Strength Index | 69.09 |
Scopus Biopharma Risk Indicators
The analysis of Scopus Biopharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Scopus Biopharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting scopus otc stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 7.49 | |||
| Standard Deviation | 14.9 | |||
| Variance | 221.89 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Scopus Biopharma
The number of cover stories for Scopus Biopharma depends on current market conditions and Scopus Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Scopus Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Scopus Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Scopus Biopharma Short Properties
Scopus Biopharma's future price predictability will typically decrease when Scopus Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Scopus Biopharma often depends not only on the future outlook of the potential Scopus Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Scopus Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 13.4 M | |
| Cash And Short Term Investments | 7.9 M |
Additional Tools for Scopus OTC Stock Analysis
When running Scopus Biopharma's price analysis, check to measure Scopus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scopus Biopharma is operating at the current time. Most of Scopus Biopharma's value examination focuses on studying past and present price action to predict the probability of Scopus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scopus Biopharma's price. Additionally, you may evaluate how the addition of Scopus Biopharma to your portfolios can decrease your overall portfolio volatility.